Patents by Inventor Jonathan Rudolph
Jonathan Rudolph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11962560Abstract: Disclosed herein is a computing device and data store for use in the storage and retrieval of communication objects. The computing device can receive a first communication sent using a first communication modality and a second communication sent using a second communication modality. The computing device can determine that the first communication and the second communication correspond to a single interaction. The computing device can generate a communication object with a communications in a particular structure consistent across communication modalities using the first communication and the second communication. The computing device can determine contexts from the communication object and store the communication object in a database with the contexts. The computing device can retrieve the communication object in response to a search request based on the contexts.Type: GrantFiled: May 13, 2022Date of Patent: April 16, 2024Assignee: ACTIANCE, INC.Inventors: John Onusko, Gopalakrishnan Ramanujam, Jonathan Rudolph
-
Publication number: 20220278953Abstract: Disclosed herein is a computing device and data store for use in the storage and retrieval of communication objects. The computing device can receive a first communication sent using a first communication modality and a second communication sent using a second communication modality. The computing device can determine that the first communication and the second communication correspond to a single interaction. The computing device can generate a communication object with a communications in a particular structure consistent across communication modalities using the first communication and the second communication. The computing device can determine contexts from the communication object and store the communication object in a database with the contexts. The computing device can retrieve the communication object in response to a search request based on the contexts.Type: ApplicationFiled: May 13, 2022Publication date: September 1, 2022Inventors: John ONUSKO, Gopalakrishnan RAMANUJAM, Jonathan RUDOLPH
-
Patent number: 11336604Abstract: A computing device can receive communications sent using one or more communication modalities. The communications can be determined to be a single interaction. A communication object can be generated for the single interaction with a structure being consistent across different communication modalities. A policy can be identified that defines which communication objects to review. The communications can be reviewed along with one or more additional communications similar to the communication object.Type: GrantFiled: December 7, 2020Date of Patent: May 17, 2022Assignee: ACTIANCE, INC.Inventors: John Onusko, Gopalakrishnan Ramanujam, Jonathan Rudolph
-
Publication number: 20210160208Abstract: A computing device can receive communications sent using one or more communication modalities. The communications can be determined to be a single interaction. A communication object can be generated for the single interaction with a structure being consistent across different communication modalities. A policy can be identified that defines which communication objects to review. The communications can be reviewed along with one or more additional communications similar to the communication object.Type: ApplicationFiled: December 7, 2020Publication date: May 27, 2021Inventors: John ONUSKO, Gopalakrishnan RAMANUJAM, Jonathan RUDOLPH
-
Patent number: 10880254Abstract: Provided herein are methods, systems, and computer-program products for providing a supervision system for review of one or more communications associated with an enterprise. The supervision system may be configured to identify the one or more communications from communications associated with the enterprise. A communication may be identified for review according to one or more policies. A policy may indicate criteria that are defined by an enterprise that indicate a communication that should be reviewed. After the communication is identified for review, the communication may be analyzed using one or more filters. A filter may indicate when a communication should not be reviewed, even when the communication is identified for review based on a policy. After a communication is both identified by a policy and not filtered by a filter, the communication may be added to a queue. A queue may be used to organize communications to be reviewed.Type: GrantFiled: October 31, 2017Date of Patent: December 29, 2020Assignee: ACTIANCE, INC.Inventors: John Onusko, Gopalakrishnan Ramanujam, Jonathan Rudolph
-
Publication number: 20180124001Abstract: Provided herein are methods, systems, and computer-program products for providing a supervision system for review of one or more communications associated with an enterprise. The supervision system may be configured to identify the one or more communications from communications associated with the enterprise. A communication may be identified for review according to one or more policies. A policy may indicate criteria that are defined by an enterprise that indicate a communication that should be reviewed. After the communication is identified for review, the communication may be analyzed using one or more filters. A filter may indicate when a communication should not be reviewed, even when the communication is identified for review based on a policy. After a communication is both identified by a policy and not filtered by a filter, the communication may be added to a queue. A queue may be used to organize communications to be reviewed.Type: ApplicationFiled: October 31, 2017Publication date: May 3, 2018Applicant: Actiance, Inc.Inventors: John ONUSKO, Gopalakrishnan RAMANUJAM, Jonathan RUDOLPH
-
Patent number: 9526731Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: December 8, 2014Date of Patent: December 27, 2016Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
-
Publication number: 20150094520Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventors: Carl R. ILLIG, Shelley K. BALLENTINE, Jinsheng CHEN, Sanath K. MEEGALLA, M. Jonathan RUDOLPH, Mark J. WALL, Kenneth J. WILSON, Renee Louise DESJARLAIS, Carl M. MANTHEY, Christopher J. MOLLOY
-
Patent number: 8933091Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: September 6, 2013Date of Patent: January 13, 2015Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
-
Patent number: 8697716Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: April 19, 2007Date of Patent: April 15, 2014Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Balltentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. DesJarlais, Carl L. Manthey, Christopher J. Molloy
-
Publication number: 20140005225Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
-
Patent number: 7795279Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: October 17, 2006Date of Patent: September 14, 2010Assignee: Janssen Pharmaceutica NVInventors: Shelley K. Ballentine, Christian Andrew Baumann, Jinsheng Chen, Carl R. Illig, Sanath K. Meegalla, M. Jonathan Rudolph, Robert W. Tuman, Mark J. Wall, Kenneth Wilson, Dana L. Johnson
-
Patent number: 7705042Abstract: The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: October 20, 2005Date of Patent: April 27, 2010Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath Meegalla, Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee DesJarlais, Carl L. Manthey, Christopher M. Flores, Christopher J. Molloy
-
Patent number: 7662837Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: October 20, 2005Date of Patent: February 16, 2010Assignee: Janssen Pharmaceutica N.V.Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. Desjarlais, Carl L. Manthey, Christopher Flores, Christopher J. Molloy
-
Patent number: 7645755Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: April 20, 2006Date of Patent: January 12, 2010Assignee: Janssen Pharmaceutical N.V.Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. Desjarlais, Carl L. Manthey, Christopher Flores, Christopher J. Molloy
-
Patent number: 7109354Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: GrantFiled: May 28, 2003Date of Patent: September 19, 2006Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
-
Publication number: 20060100201Abstract: The invention relates to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: October 20, 2005Publication date: May 11, 2006Inventors: Carl Illig, Shelley Ballentine, Jinsheng Chen, Sanath Meegalla, M. Jonathan Rudolph, Mark Wall, Kenneth Wilson, Renee DesJarlais, Carl Manthey, Christopher Flores, Christopher Molloy
-
Publication number: 20040009995Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1Type: ApplicationFiled: May 28, 2003Publication date: January 15, 2004Applicant: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
-
Patent number: 6562840Abstract: The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1—R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.Type: GrantFiled: February 26, 2002Date of Patent: May 13, 2003Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Juan José Marugán
-
Patent number: 6515002Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.Type: GrantFiled: September 26, 2001Date of Patent: February 4, 2003Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Roger F. Bone, Scott L. Klein, Troy L. Randle